Contrary to the clinical effectiveness of anti-CTLA-4 Ab, several immunotoxicities such as autoimmune colitis, dermatitis, hepatitis, hypophysitis and thyrotoxicosis were observed in the treated patients26–29. This evidence concerns the gene CTLA4 and hepatitis A virus infection.